These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37712639)

  • 1. Precision detection of recent HIV infections using high-throughput genomic incidence assay.
    Faraci G; Park SY; Love TMT; Dubé MP; Lee HY
    Microbiol Spectr; 2023 Sep; 11(5):e0228523. PubMed ID: 37712639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing high-throughput HIV incidence assay with pyrosequencing platform.
    Park SY; Goeken N; Lee HJ; Bolan R; Dubé MP; Lee HY
    J Virol; 2014 Mar; 88(5):2977-90. PubMed ID: 24371062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HIV Genomic Incidence Assay Meets False Recency Rate and Mean Duration of Recency Infection Performance Standards.
    Park SY; Love TMT; Reynell L; Yu C; Kang TM; Anastos K; DeHovitz J; Liu C; Kober KM; Cohen M; Mack WJ; Lee HY
    Sci Rep; 2017 Aug; 7(1):7480. PubMed ID: 28785052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microdrop Human Immunodeficiency Virus Sequencing for Incidence and Drug Resistance Surveillance.
    Park SY; Faraci G; Murphy G; Pilcher C; Busch MP; Lee HY
    J Infect Dis; 2021 Sep; 224(6):1048-1059. PubMed ID: 33517458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of HIV Recency Assays for HIV Incidence Estimation and Other Surveillance Use Cases: Systematic Review.
    Facente SN; Grebe E; Maher AD; Fox D; Scheer S; Mahy M; Dalal S; Lowrance D; Marsh K
    JMIR Public Health Surveill; 2022 Mar; 8(3):e34410. PubMed ID: 35275085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody avidity-based approach to estimate population-level incidence of hepatitis C.
    Boon D; Bruce V; Patel EU; Quinn J; Srikrishnan AK; Shanmugam S; Iqbal S; Balakrishnan P; Sievers M; Kirk GD; Thomas DL; Quinn TC; Cox AL; Page KA; Solomon SS; Mehta SH; Laeyendecker O
    J Hepatol; 2020 Aug; 73(2):294-302. PubMed ID: 32240715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of Bio-Rad and Limiting Antigen Avidity Assays in Detecting Recent HIV Infections Using the Quebec Primary HIV-1 Infection Cohort.
    Serhir B; Hamel D; Doualla-Bell F; Routy JP; Beaulac SN; Legault M; Fauvel M; Tremblay C;
    PLoS One; 2016; 11(5):e0156023. PubMed ID: 27224023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations.
    Kirkpatrick AR; Patel EU; Celum CL; Moore RD; Blankson JN; Mehta SH; Kirk GD; Margolick JB; Quinn TC; Eshleman SH; Laeyendecker O
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):756-62. PubMed ID: 26988426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance.
    Sempa JB; Welte A; Busch MP; Hall J; Hampton D; Facente SN; Keating SM; Marson K; Parkin N; Pilcher CD; Murphy G; Grebe E;
    PLoS One; 2019; 14(7):e0220345. PubMed ID: 31348809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing Biases in the Evaluation of Classification Assays for HIV Infection Recency.
    Patterson-Lomba O; Wu JW; Pagano M
    PLoS One; 2015; 10(10):e0139735. PubMed ID: 26436915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroconverting blood donors as a resource for characterising and optimising recent infection testing algorithms for incidence estimation.
    Kassanjee R; Welte A; McWalter TA; Keating SM; Vermeulen M; Stramer SL; Busch MP
    PLoS One; 2011; 6(6):e20027. PubMed ID: 21694760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance characteristics of an antibody-based multiplex kit for determining recent HIV-1 infection.
    Curtis KA; Hanson DL; Price KA; Owen SM
    PLoS One; 2017; 12(5):e0176593. PubMed ID: 28472089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infection Staging and Incidence Surveillance Applications of High Dynamic Range Diagnostic Immuno-Assay Platforms.
    Grebe E; Welte A; Hall J; Keating SM; Facente SN; Marson K; Martin JN; Little SJ; Price MA; Kallas EG; Busch MP; Pilcher CD; Murphy G
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):547-555. PubMed ID: 28914669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 envelope sequence-based diversity measures for identifying recent infections.
    Kafando A; Fournier E; Serhir B; Martineau C; Doualla-Bell F; Sangaré MN; Sylla M; Chamberland A; El-Far M; Charest H; Tremblay CL
    PLoS One; 2017; 12(12):e0189999. PubMed ID: 29284009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIITE: HIV-1 incidence and infection time estimator.
    Park SY; Love TMT; Kapoor S; Lee HY
    Bioinformatics; 2018 Jun; 34(12):2046-2052. PubMed ID: 29438560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designing a genome-based HIV incidence assay with high sensitivity and specificity.
    Park SY; Love TM; Nelson J; Thurston SW; Perelson AS; Lee HY
    AIDS; 2011 Oct; 25(16):F13-9. PubMed ID: 21716075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual testing algorithm of BED-CEIA and AxSYM Avidity Index assays performs best in identifying recent HIV infection in a sample of Rwandan sex workers.
    Braunstein SL; Nash D; Kim AA; Ford K; Mwambarangwe L; Ingabire CM; Vyankandondera J; van de Wijgert JH
    PLoS One; 2011 Apr; 6(4):e18402. PubMed ID: 21532753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.